Radius Health to Host Scientific Panel Discussion for Investors on Investigational Drug Abaloparatide at ASBMR 2014
GlobeNewswire - Mon Sep 08, 6:36AM CDT
Live Panel And Conference Call Scheduled for 7:30 a.m. CDT on September 15, 2014
Radius Health Reports Proof of Mechanism for RAD1901 and Presentation at 4th Annual Brain Metastases Research and Emerging Therapy Conference in September
GlobeNewswire - Thu Aug 28, 4:19PM CDT
Radius Health, Inc. ("Radius"
Radius Health Announces Presentations at the American Society for Bone and Mineral Research 2014 Annual Meeting
GlobeNewswire - Tue Aug 19, 6:37AM CDT
Radius Health, Inc. (Nasdaq:RDUS) announced today that it will present new data from multiple studies of abaloparatide in women with postmenopausal osteoporosis at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Texas.
Radius Health Reports Second Quarter 2014 Financial and Operating Results
GlobeNewswire - Tue Aug 12, 6:48AM CDT
Radius Health, Inc. ("Radius"
Radius Health to Present at the Canaccord Genuity 34th Annual Growth Conference
GlobeNewswire - Thu Aug 07, 9:43AM CDT
Radius Health (Nasdaq:RDUS) announced today that its President and CEO, Robert Ward, will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014 at 10:30 a.m. Eastern Time at the Intercontinental Hotel in Boston.
Radius Health to Announce Second Quarter 2014 Financial Results, Host Conference Call and Live Webcast on Aug 12, 2014
GlobeNewswire - Wed Aug 06, 6:57AM CDT
Radius Health (Nasdaq:RDUS) announced today that it will release its second quarter 2014 financial results on Tuesday, August 12, 2014.
Nasdaq stocks posting largest percentage increases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Radius Health, Inc. (NASDAQ: RDUS) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Jul 30, 9:07AM CDT
What:
Oxford Immunotec Appoints Louis O'Dea Chief Medical Officer
GlobeNewswire - Mon Jul 07, 6:00AM CDT
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology, today announced that Louis O'Dea, MB, BCh, BAO, has joined the company as Chief Medical Officer. Dr. O'Dea brings to Oxford Immunotec more than 20 years of worldwide pharmaceutical, medical device, and biotechnology industry management experience. Dr. O'Dea will support the continued growth of our current T-SPOT.TB business and the development of new products through management of our medical education and clinical trial programs. Prior to joining Oxford Immunotec, Dr. O'Dea served as the Chief Medical Officer and Head of Regulatory Affairs at Moderna Therapeutics. Prior to Moderna, he was Chief Medical Officer of Radius Health, Inc. and Head of Clinical Development for the Metabolic and Reproductive Health unit of Serono, a division of Merck.
Oxford Finance and Solar Capital Close $30 Million Senior Debt Facility with Radius Health
PR Newswire - Tue Jul 01, 8:00AM CDT
Oxford Finance LLC ("Oxford"